Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ICBs may rarely cause immune-related infectious complications, including re-activation of latent t...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasopoulou, Amalia, Ziogas, Dimitrios C., Samarkos, Michael, Kirkwood, John M., Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727332/
https://www.ncbi.nlm.nih.gov/pubmed/31484550
http://dx.doi.org/10.1186/s40425-019-0717-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727332/
https://www.ncbi.nlm.nih.gov/pubmed/31484550
http://dx.doi.org/10.1186/s40425-019-0717-7

Ejemplares similares